Pik3ca Mutations clinical trials

Explore recruiting pik3ca mutations clinical trials.

Recruiting pik3ca mutations studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pik3ca Mutations trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway

Finland, Sweden, Denmark, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Inavolisib for PIK3CA mutated advanced endometrial cancer:a multicentric, phase II, MITO END-4 trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, open-label, randomized, 2-arm, phase II study to evaluate the efficacy and safety of cetuximab plus irinotecan rechallenge compared with investigator's choice of therapy in the third-line setting in ctDNA genomically selected patients with metastatic colorectal cancer (CITRIC Study)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Pik3ca Mutations trials by city

Pik3ca Mutations in Toronto Pik3ca Mutations in Vancouver Pik3ca Mutations in Montreal Pik3ca Mutations in Calgary Pik3ca Mutations in Edmonton Pik3ca Mutations in Ottawa Pik3ca Mutations in Winnipeg Pik3ca Mutations in Quebec City Pik3ca Mutations in Hamilton Pik3ca Mutations in Kitchener Pik3ca Mutations in London Pik3ca Mutations in Halifax Pik3ca Mutations in New York Pik3ca Mutations in Los Angeles Pik3ca Mutations in Chicago Pik3ca Mutations in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease